{
    "nctId": "NCT02530008",
    "briefTitle": "Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer",
    "officialTitle": "Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Women With Suspected or Confirmed Recurrent Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 600,
    "primaryOutcomeMeasure": "subjects with detectable DTCs/CTCs",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically-confirmed breast cancer - based upon pathology report of the primary or metastatic diagnosis\n* Recurrent breast cancer (local, regional, or distant disease) - as determined by either clinical,radiological, or pathological evaluation\n* Willing to undergo or provide tissue from a recent biopsy of recurrent tumor for both clinical and research testing\n* Willing to undergo blood specimen collection\n* Age 18 or over and are able to give informed consent\n\nExclusion Criteria:\n\n* Non-metastatic breast cancer (stage I, II or III)\n* Anticoagulation that cannot be interrupted for the purpose of study evaluation (patients must have normal INR and PTT at the time of study biopsy)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}